September 26, 2019
Takeda Pharmaceutical said on September 25 that the results of a PII study of its investigational oral antiviral compound TAK-620 (maribavir) in patients with cytomegalovirus (CMV) infection after undergoing hematopoietic stem cell or solid organ transplants, show treatment efficacy in...read more